Please login to the form below

Not currently logged in
Email:
Password:

BlackThorn Therapeutics appoints CEO

Gregory Vontz joins from Topica Pharmaceuticals

BlackThorn Therapeutics Gregory VontzSan Francisco, US-based biotech BlackThorn Therapeutics has appointed Gregory Vontz as its new chief executive officer.

Vontz brings over 30 years of biotech and pharma industry experience to the role, joining from fungal infection specialist Tropica Pharmaceuticals where he also served as chief executive.

Prior to this, Vontz was president and chief operating officer of Connetics Corporation, spent 12 years in a series of senior marketing and product development roles at Genentech, and worked in sales and sales management at Merck & Co.

Dr Mark Corrigan, chairman of the board at BlackThorn, said: “On behalf of the Board and the BlackThorn team, I am pleased to welcome Greg as our new chief executive officer.

“His experience as a biotech executive, record of successful drug development and strategic transactions will serve BlackThorn well in advancing the company's mission to develop new treatments for patients suffering from neurobehavioral disorders.”

17th February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics